VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026.
In light of the previously announced proposed acquisition of Theravance Biopharma, Zymeworks has elected not to host a second quarter earnings conference call after release of its financial results. We look forward to providing an update following the expected closing of the proposed acquisition of Theravance Biopharma, sharing greater visibility into the combined business and its strategic priorities.
About Zymeworks Inc.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks’ asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com
View the Zacks #1 Rank List
Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026
Zymeworks will report Q2 2026 financial results on August 6, not hosting a conference call due to pending acquisition.
Quiver AI Summary
Zymeworks Inc. announced that it will release its second quarter 2026 financial results on August 6, 2026, after the market closes, but will not hold an earnings conference call due to its planned acquisition of Theravance Biopharma. The company focuses on developing multifunctional biotherapeutics, managing a licensed healthcare portfolio, and aims to improve care for difficult diseases like cancer and autoimmune conditions. Zymeworks is advancing its product pipeline, which includes the bispecific antibody Ziihera, developed using its proprietary Azymetric technology, and has formed partnerships with firms like BeOne Medicines and Jazz Pharmaceuticals for commercializing its products. The company plans to share insights on the integration and strategic priorities after the acquisition closes.
Potential Positives
Potential Negatives
FAQ
When will Zymeworks report its Q2 2026 financial results?
Zymeworks will report its second quarter 2026 financial results after market close on August 6, 2026.
Will there be a conference call for the Q2 earnings report?
No, Zymeworks has elected not to host a conference call following the Q2 earnings release.
What is the focus of Zymeworks' business?
Zymeworks focuses on managing a portfolio of licensed healthcare assets and developing novel biotherapeutics for difficult-to-treat diseases.
What technology does Zymeworks use for its therapies?
Zymeworks uses its proprietary Azymetric™ technology to engineer and develop bispecific antibodies like Ziihera.
Who can I contact for investor inquiries about Zymeworks?
For investor inquiries, contact Shrinal Inamdar, VP of Investor Relations, at (604) 678-1388 or ir@zymeworks.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZYME Revenue
$ZYME had revenues of $2.4M in Q1 2026. This is a decrease of -91.12% from the same period in the prior year.
You can track ZYME financials on Quiver Quantitative's ZYME stock page.
You can access data on ZYME stock through the Quiver Quantitative API.
$ZYME Hedge Fund Activity
We have seen 93 institutional investors add shares of $ZYME stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ZYME Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 6 analysts offer price targets for $ZYME in the last 6 months, with a median target of $46.5.
Here are some recent targets:
Full Release
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026.
In light of the previously announced proposed acquisition of Theravance Biopharma, Zymeworks has elected not to host a second quarter earnings conference call after release of its financial results. We look forward to providing an update following the expected closing of the proposed acquisition of Theravance Biopharma, sharing greater visibility into the combined business and its strategic priorities.
About Zymeworks Inc.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks’ asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com
Read full article here »